Adaptive Biotechnologies (ADPT) Asset Writedowns and Impairment (2024 - 2026)

Adaptive Biotechnologies (ADPT) has 3 years of Asset Writedowns and Impairment data on file, last reported at $347000.0 in Q1 2026.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $347000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $910000.0 (changed N/A YoY) and the FY2025 annual result came in at $563000.0, down 70.95% from the prior year.
• Asset Writedowns and Impairment slipped to $347000.0 in Q1 2026 per ADPT's latest filing, from $563000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $563000.0 in Q4 2025, with the low at -$5.3 million in Q4 2024.
• Average Asset Writedowns and Impairment over 3 years is -$1.5 million, with a median of $347000.0 recorded in 2026.
• The widest YoY moves for Asset Writedowns and Impairment: up 110.69% in 2025, down 110.69% in 2025.
• Adaptive Biotechnologies' Asset Writedowns and Impairment stood at -$5.3 million in 2024, then surged by 110.69% to $563000.0 in 2025, then plunged by 38.37% to $347000.0 in 2026.
• Business Quant data shows ADPT's Asset Writedowns and Impairment at $347000.0 in Q1 2026, $563000.0 in Q4 2025, and -$5.3 million in Q4 2024.